Key facts
- It has raised $580K; the latest was Accelerator/Incubator in Sep 2025.
- Notable investors include Almi Invest, 1stRound, UU Invest, Uppsala Innovation Centre.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Mesenkia Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Mesenkia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mesenkia Therapeutics
Developer of a healthcare research company intended to develop a new drug for glioblastoma. The company focuses on prolonging progression-free survival for aggressive primary and recurrent glioblastoma by inhibiting the proliferation of tumor- and glioma stem cells and reducing their capacity to invade and spread by targeting two different mechanisms, enabling patients with an antibody treatment that both stimulates the body's immune system and slows tumor growth.
- Sector
- Healthcare
- HQ
- Uppsala, Sweden
- Founded
- 2023
- Employees
- 6
- Website
- mesenkia.com/
- Ownership
- Privately Held (backing)
Mesenkia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mesenkia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mesenkia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.